Search

Displaying results 7741 - 7750 of 10000 in total
  1. Drug

    EU204

    go.drugbank.com/drugs/DB17438
    Investigational

    EU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.

    Synonyms: EBV-induced natural T cell [EBViNT Cell]
  2. Drug

    Allovectin-7

    go.drugbank.com/drugs/DB17439
    Investigational

    Allovectin-7 or allovectin-7(r) is a lipid complex that contains the DNA sequences encoding HLA-B7 and beta-2 microglobulin.

    Synonyms: Allovectin-7(r), Allovectin-7
  3. Drug

    Lym-1-I-131

    go.drugbank.com/drugs/DB17445
    Experimental

    Lym-1-I-131 is a monoclonal antibody labeled with iodine-131 (131I) that preferentially targets malignant lymphocytes.

    Synonyms: Monoclonal antibody LYM-1-I-131, Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma
  4. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    Linvoseltamab (INN), marketed as Lynozyfic™, is a bispecific human IgG4 monoclonal antibody developed by Regeneron that promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma … This mechanism results in the targeted release of cytokines such as IL-2, IL-6, and IFN-gamma, promoting the selective lysis of BCMA-expressing cells and offering a novel immunotherapeutic approach for

    Synonyms: human IgG4-based anti-CD3 x anti-BCMA bispecific monoclonal antibody that binds to CD3 and BCMACategories: Bispecific B Cell Maturation Antigen-directed CD3 T Cell Engager
  5. Drug

    Tusamitamab ravtansine

    go.drugbank.com/drugs/DB17448
    Investigational

    Tusamitamab ravtansine is an antibody-drug conjugate that targets carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5).

  6. Drug

    Serplulimab

    go.drugbank.com/drugs/DB17451
    ApprovedInvestigational

    Serplulimab is a humanized monoclonal IgG4 antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death-1 (PD-1) receptor. … It was first approved in China - where it is indicated for a number of different cancers[L52963] - and has since been approved in several southeast Asian countries.

    Synonyms: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
  7. Drug

    MK-0482

    go.drugbank.com/drugs/DB17453
    Investigational

    MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.

  8. Drug

    RO-7293583

    go.drugbank.com/drugs/DB17455
    Investigational

    RO-7293583 is a TYRP1-Targeting CD3 T-Cell Engager.

  9. Drug

    gp209-2M antigen

    go.drugbank.com/drugs/DB17462
    Investigational

    The gp209-2M antigen is derived from gp209, and has potential immunomodulatory and antineoplastic activities.

  10. Drug

    ETBX-011

    go.drugbank.com/drugs/DB17464
    Investigational

    ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).